Britain and America have forged a landmark trade agreement that will ensure zero levies on UK drug shipments going into the US market.
Key Provisions of the Accord
As part of the deal, the UK has committed to raise spending on medicines through the NHS. This commitment secures that duties on these key exports will remain at zero for a timeframe of 36 months.
This agreement comes after earlier warnings to significantly raise duties on patented pharmaceutical products, with increases mentioned reaching one hundred percent.
"This arrangement between the UK strengthens the global environment for cutting-edge drugs and introduces long-overdue equity to transatlantic pharmaceutical trade," a statement noted.
Trade Significance
Medicines are one of the the United Kingdom's most significant export categories to the America, which is easily the largest buyer for large UK drugmakers.
Export figures show that in the year prior to the third quarter, the UK exported pharmaceutical products totaling billions to the US. This amount made up 17.4% of British export trade in that span.
"This agreement secures employment, boosts capital expenditure and facilitates the UK to emerge as a international leader for life sciences," the Business and Trade Secretary remarked.
Specific NHS Changes
The agreement involves several specific changes from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new medicines to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a target to double overall health service expenditure on medicines from 0.3% of the national economy to 0.6 percent over the next decade.
- Payback Limit: The amount manufacturers must return to the NHS to prevent overspending will be capped at fifteen percent. In the past, refunds topped twenty percent.
Recent Tensions
The pact follows a long-running row between the drug companies and the ministers over spending levels and NHS adoption.
This friction were exacerbated by arguments that American customers were charged a premium for the same drugs than people in the other developed nations.
Recently, several major drug company projects in the UK have been halted or scrapped, while substantial expansions have been announced toward projects in the United States.
A senior figure acknowledged that the NHS needed to spend more on medicines, noting that its spending on drugs had declined as a proportion of its total funding over the past decade.
